Concomitant oral and intravenous pharmacokinetics of trametinib a MEK inhibitor in subjects with solid tumours

摘要

AimsThe aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2 mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.